The role of ibrutinib in COVID-19 hyperinflammation: A case report April 2021

[zaax]

In case anyone missed this when posted a year+ ago

sciencedirect.com/science/a...

[AussieNeil Partner Administrator]

Following on from your referenced case report from April 2021 and this report the following June, Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19 pubmed.ncbi.nlm.nih.gov/342... , in December 2021 we had The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review ncbi.nlm.nih.gov/pmc/articl...

Conclusions

It is recommended that patients continue their medications in this class if they develop COVID-19 and were receiving these agents before the disease developed. The use of BTK inhibitors might enable patients to experience less severe immune responses to the COVID-19. Well-designed studies are needed to evaluate the effectiveness of BTKis in the management of COVID-19.

At least two clinical trials resulted; Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization (NCT04439006 - 10 patients) and Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury (iNSPIRE) (NCT04375397 - 46 patients)

I couldn't find a report for the 10 patient trial, but we have this report on the 46 patient trial from March this year:-

Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study pubmed.ncbi.nlm.nih.gov/342...

Conclusions: Addition of ibrutinib to SOC did not improve the proportion of patients alive and without respiratory failure through day 28 in hospitalized patients with severe COVID-19. Ibrutinib had a manageable safety profile, with similar safety to placebo.

The recommendation to continue taking BTKi medication (acalabrutinib, ibrutinib or zanubrutinib) if you develop a COVID-19 infection still stands, but unfortunately, the hope that starting a BTKi drug when infected would prove beneficial, didn't prove to be the case.

Neil